Resverlogix to Participate in Leading Scientific Conferences
October 29, 2021 08:30 ET
|
Resverlogix Corp
Presentations will Showcase Research by Resverlogix Scientists, Advancing our Understanding of Epigenetics in Chronic Diseases CALGARY, Alberta, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp....
Resverlogix to Present at Upcoming Conferences
October 13, 2021 08:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and...
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
October 12, 2021 16:35 ET
|
Resverlogix Corp
CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the...
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
September 13, 2021 08:00 ET
|
Resverlogix Corp
Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a...
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
September 08, 2021 08:00 ET
|
Resverlogix Corp
Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular Resistance (PVR) and Was Well Tolerated Successful Completion and Promising Results of...
Resverlogix Announces Management Change
July 06, 2021 06:00 ET
|
Resverlogix Corp
CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate...
Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
June 23, 2021 00:16 ET
|
Resverlogix Corp
CALGARY, Alberta, June 22, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in...
Resverlogix 與 EVERSANA 宣佈建立合作夥伴關係，以支持用於治療 2019 冠狀病毒病的 apabetalone 在美國和加拿大的初期商業化活動
June 04, 2021 09:17 ET
|
Resverlogix Corp
亞伯達省卡加利和芝加哥, June 04, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (Resverlogix) (TSX:RVX) 與全球生命科學行業下一代商業服務的先驅 EVERSANA™ 今天宣佈建立合作夥伴關係，以支持 apabetalone 計劃在美國和加拿大（已授權對用於治療 2019 冠狀病毒病的 apabetalone...
Resverlogix和EVERSANA宣布合作以支持即将在美国和加拿大启动的Apabetalone初始商业化
June 04, 2021 09:17 ET
|
Resverlogix Corp
阿尔伯塔省卡尔加里和芝加哥, June 04, 2021 (GLOBE NEWSWIRE) -- Resverlogix...
Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
June 03, 2021 08:04 ET
|
Resverlogix Corp
CALGARY, Alberta and CHICAGO, June 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next generation commercial services to the global life...